James Uyeki, MD
Medical Oncology · Austin, TXNPI 1124187927
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $454 of the $607 with a category attached, or 74.8%. It is spread thinly across 17 manufacturers, the largest accounting for just 20.1%. 2025 is the largest year on record at $279, 2.1 times the $136 reported in 2019. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 23 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$122
- Johnson & Johnson$104
- E.r. Squibb & Sons, L.L.C.$55
- Novartis$44
- Sanofi$42
- AbbVie$30
- plus $210 from 11 others
Across 800 payments — averaging $5783.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.3M
- E.r. Squibb & Sons, L.L.C.$1.2M
- Eli Lilly$568K
- Mirati Therapeutics, Inc.$434K
- Genentech, Inc.$401K
- Janssen Research & Development, LLC$181K
- plus $521K from 12 others
What the payments were for
- Food & beverage$45475%
- Education$15325%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Johnson & Johnson | 3 | $104 |
| E.r. Squibb & Sons, L.L.C. | 3 | $55 |
| Novartis | 2 | $44 |
| Sanofi | 2 | $42 |
| AbbVie | 1 | $30 |
| Genmab U.S., Inc. | 1 | $30 |
| Incyte Corporation | 1 | $26 |
| AstraZeneca | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $14 |
| Gilead | 1 | $12 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYXEOS$122
How this compares
$607 in reported general payments places this provider in the 20th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 64 | $910,681 |
| RevlimidLenalidomide | 55 | $873,659 |
| PomalystPomalidomide | 23 | $419,628 |
| TagrissoOsimertinib Mesylate | 21 | $339,881 |
| InlytaAxitinib | 23 | $298,095 |
| Abiraterone Acetate | 50 | $223,454 |
| ErleadaApalutamide | 15 | $210,301 |
| VenclextaVenetoclax | 16 | $203,872 |
| VerzenioAbemaciclib | 14 | $197,115 |
| BosulifBosutinib | 20 | $145,408 |
| TasignaNilotinib Hcl | 14 | $138,992 |
| CreonLipase/Protease/Amylase | 21 | $99,787 |
| XareltoRivaroxaban | 100 | $92,759 |
| EliquisApixaban | 61 | $51,637 |
| VeozahFezolinetant | 11 | $6,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $14 | $873,65955 claims |
| PfizerInlyta, Bosulif, Eliquis | $12 | $495,140104 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $55 | $419,62823 claims |
| AstraZenecaTagrisso | $25 | $339,88121 claims |
| AbbVieVenclexta, Creon | $30 | $303,65937 claims |
| Johnson & JohnsonErleada, Xarelto | $104 | $303,059115 claims |
| NovartisTasigna | $44 | $138,99214 claims |
| Astellas Pharma US IncVeozah | $20 | $6,36811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Austin
- Sue EckhardtAustin$1.5M
- Miguel AlbinoAustin$322K
- Jason MelearAustin$229K
- Andrew BrennerAustin$125K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.